go-v.orgdoi

Triple-negative breast cancer and new treatment developments

Stephen Dyar, Alvaro Moreno‐Aspitia · Clinical Investigation · 2011

  • DOI 10.4155/cli.11.87
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2011

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2011

Abstract

Triple-negative breast cancer (TNBC) is an aggressive immunohistochemical phenotype found in approximately 15% of women with invasive breast cancer. Although TNBC is sensitive to cytotoxic chemotherapy, it is associated with poorer outcomes. Moreover, patients with TNBC are not candidates for hormonal or human epidermal growth factor 2-targeted therapies, thus underscoring the need for new treatments for TNBC. Agents targeting aberrant DNA repair, including platinum and PARP-1 inhibitors, are under evaluation in TNBC based on its overlap with BRCA1-related breast cancer.

Several other cytotoxic (e.g., ixabepilone) and targeted agents (e.g., bevacizumab, cetuximab, everolimus and dasatinib) are also being investigated clinically. Results from early clinical trials suggest the potential for improving the outcomes of patients with TNBC in the future.

Open the resolved locator · 10.4155/cli.11.87

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 00:27 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.11.87
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.